Episurf accelerates shift to pure-play property company, winds down medtech operations

• Episurf Medical will accelerate its shift into a pure-play Nordic property company, reallocating capital and resources to its real estate platform.
• The board launched an orderly wind-down of the operating medtech business, citing weak feasibility and high time and capital demands for a sale or spin-off.
• Focus will shift to monetizing the patent portfolio and other intangible assets, rather than continuing in-house production and operations.
• FDA feedback in the Episealer MTP 510(k) process called for additional validation data, increasing required investment and timelines for US clearance.
• The medtech wind-down is expected to lower the cost base, supporting earnings from Q2 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Episurf Medical AB published the original content used to generate this news brief via Cision (Ref. ID: 20260822:BIT:0845:0) on August 22, 2026, and is solely responsible for the information contained therein.